Category - Developments

Developments

Tryp Therapeutics files IND for Phase 2a eating disorders study

Tryp Therapeutics (CSE TRYP; OTCQB:TRYPF) submitted an IND with the FDA to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders. The trial is being conducted...

September 23, 2021

Developments

Cognetivity Neurosciences to place ICA system in Dubai

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) reached its first commercial agreement for the Integrated Cognitive Assessment (ICA) to be deployed at the Clemenceau Medical Center (CMC) in Dubai. CMC is...

September 22, 2021

Developments

FSD Pharma acquires Lucid Psycheceuticals

FSD Pharma (NASDAQ, CSE:HUGE; FRA:0K9) completed the acquisition of Lucid Psycheceuticals, a Toronto-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat mental health...

September 21, 2021

Developments

Profound Medical gets recommendation from Timelo Investment

During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN). “Profound has an FDA-approved...

September 20, 2021

Developments

Health Canada clears first-in-man study of OpSens guidewire

OpSens (TSX:OPS; OTCQX:OPSSF) received Health Canada’s approval to begin a first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement (TAVR). The...

September 20, 2021

Developments

Heritage Cannabis launches first Opticann CB4 medical products in Canada

Heritage Cannabis (CSE:CANN; OTCQX:HERTF) announced that Opticann, the medical brand and subsidiary of Heritage, is launching its first suite of CB4 branded products and has launched Opticann.ca in Canada...

September 20, 2021

Developments

atai Life Sciences amends loan agreement to support IntelGenx upgrade to TSX

atai Life Sciences (NASDAQ;ATAI) amended a loan agreement with IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) to support IntelGenx’s conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock...

September 15, 2021

Developments

Cognetivity’s ICA to be deployed in world-leading UK dementia care practice

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) agreed with Loveday & Co. to deploy the Integrated Cognitive Assessment (ICA) in the specialist dementia and senior care provider’s practice. Loveday is the only...

September 14, 2021

Developments

PharmaJet to deliver Scancell COVID-19 DNA vaccines

Closely-held PharmaJet was selected by partner, Scancell, to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, using the PharmaJet Tropis and PharmaJet Stratis Needle-free injection...

September 14, 2021

Developments

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

Hepion Pharmaceuticals (NASDAQ:HEPA) is initiating a Phase 2b clinical trial after releasing additional positive efficacy data from its Phase 2a AMBITION trial with CRV431 for the treatment of non-alcoholic...

September 13, 2021

Category - Developments

Tryp Therapeutics files IND for Phase 2a eating disorders study

Cognetivity Neurosciences to place ICA system in Dubai

FSD Pharma acquires Lucid Psycheceuticals

Profound Medical gets recommendation from Timelo Investment

Health Canada clears first-in-man study of OpSens guidewire

Heritage Cannabis launches first Opticann CB4 medical products in Canada

atai Life Sciences amends loan agreement to support IntelGenx upgrade to TSX

Cognetivity’s ICA to be deployed in world-leading UK dementia care practice

PharmaJet to deliver Scancell COVID-19 DNA vaccines

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

General

More